Journal Article10.1002/JBM.A.36153
Controlled basic fibroblast growth factor release device made of poly(ethyleneglycol) dimethacrylates for creating a subcutaneous neovascular bed for cell transplantation.
Shinji Yamada,Nobuhiro Nagai,Saaya Saijo,Hirokazu Kaji,Matsuhiko Nishizawa,Imura Kozue,Masafumi Goto,Toshiaki Abe +7 more
4
TL;DR: A controlled bFGF releasing device could provide a neovascular bed with the required vascularization in the subcutaneous space and show a significant increase in the extent of vasculature that was dependent on the amount of bF GF loaded into the device.
read more
Abstract: Subcutaneous space is a potential site for the transplantation of cells such as islets for treatment of type 1 diabetes. To enhance engraftment, an optimal space for the growth of the transplanted cells is needed along with neovascularization. In this study, we developed a device using a photocurable resin, poly(ethyleneglycol) dimethacrylates (PEGDM), for controlled release of basic fibroblast growth factor (bFGF) to create a subcutaneous neovascular bed in rats. The device consists of a disk-shaped capsule with micropores and is composed of tri(ethyleneglycol) dimethacrylate (TEGDM) and a drug formulation of PEGDM. The release rate was tuned by changing the number of pores and the composition of water and PEGDM in the drug formulation. bFGF released from devices incubated in phosphate-buffered saline (PBS) enhanced the growth of fibroblasts, indicating bioactivity of bFGF after release. Histological evaluation showed a significant increase in the extent of vasculature that was dependent on the amount of bFGF loaded into the device. A perfusion study using fluorescein isothiocyanate dextran 2000 kDa showed linear and capillary staining patterns, indicating potent functional vasculature. In conclusion, the controlled bFGF releasing device could provide a neovascular bed with the required vascularization in the subcutaneous space. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 3017-3024, 2017.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A drug refillable device for transscleral sustained drug delivery to the retina
TL;DR: The refillable drug delivery device is a promising tool to administer drugs long‐term by reinjection with less invasiveness to intraocular tissues.
12
Effect of Basic Fibroblast Growth Factor on Xenogeneic Islets in Subcutaneous Transplantation—A Murine Model
Sin Yu Yang,Kai Chiang Yang,Shoichiro Sumi +2 more
- 01 Jun 2019
TL;DR: The findings suggest that bFGF had no beneficial effect on a 1-time operation in subcutaneous islet transplantation, and mice in the 2-time OP had relatively higher serum insulin levels with improved renal and metabolic biomarkers.
5
Effect of sustained insulin-releasing device made of poly(ethylene glycol) dimethacrylates on retinal function in streptozotocin-induced diabetic rats
Ayako Hoshi,Nobuhiro Nagai,Reiko Daigaku,Remi Motoyama,Saaya Saijo,Hirokazu Kaji,Toshiaki Abe +6 more
TL;DR: The insulin-releasing device attenuated the reduction of retinal function in STZ-induced diabetic conditions for 4 weeks and the efficacy of the device might be partially related to PKC signaling in the retina.
1
Fibrin supports subcutaneous neonatal porcine islet transplantation without the need for pre-vascularization.
TL;DR: The benefits of fibrin scaffolds are explored in enhancing the engraftment and long‐term function of NPI grafts in this ectopic site.
References
Clinical pancreatic islet transplantation.
TL;DR: The techniques required for human islet isolation, in vitro culture before the transplant and clinical islet transplantation are outlined and the potential risks, long-term outcomes and advances in treatment after the transplant are discussed to further move this treatment towards becoming a more widely available option for patients with type 1 diabetes mellitus and eventually a potential cure.
637
A prevascularized subcutaneous device-less site for islet and cellular transplantation
Andrew R. Pepper,Boris Gala-Lopez,Rena Pawlick,Shaheed Merani,Tatsuya Kin,A. M. James Shapiro +5 more
TL;DR: It is demonstrated that transient priming of a subcutaneous site supports diabetes-reversing islet transplantation in mouse models without the need for a permanent cell-encapsulation device.
343
Survival and metabolic function of syngeneic rat islet grafts transplanted in the omental pouch.
TL;DR: The results indicate that the omental pouch is a viable site which offers a safe, convenient and efficacious alternative to the renal subcapsular space to transplant islets in rodents.
144
Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation.
Yutaka Sakakibara,Kazunobu Nishimura,Keiichi Tambara,Masaya Yamamoto,Fanglin Lu,Yasuhiko Tabata,Masashi Komeda +6 more
TL;DR: Prevascularization with basic fibroblast growth factor-incorporated microspheres enhances the benefits of cardiomyocyte transplantation and is expected that this system will contribute to regeneration medicine through its extensive application to other growth factors.
144
Modulation of Mitogenic Activity of Fibroblast Growth Factors by Inorganic Polyphosphate
Toshikazu Shiba,Daisuke Nishimura,Yumi Kawazoe,Yuichiro Onodera,Kaori Tsutsumi,Rie Nakamura,Minako Ohshiro +6 more
TL;DR: Poly(P) enhanced the proliferation of normal human fibroblast cells and facilitated the FGF-2 binding to its cell surface receptors and may be a spontaneous modulator of FGFs.
142